Multi Centre, Phase Ib Safety Study of anti-fibrin humanised monoclonal antibody (DI-DD3B6/22-80B3) Fab' Protein Fragment (ThromboView) conjugated with Technetium-99m in the Detection of Pulmonary Emboli

This study tests a special imaging agent called ThromboView that may help doctors detect blood clots in the lungs (called pulmonary emboli or PE) more accurately. ThromboView is attached to a small amount of a radioactive substance and injected into the body so that doctors can use a scanner to find where blood clots are located. The study is checking how safe this new imaging method is. You may be eligible if: - You are 18 years of age or older - You have recently been diagnosed with a blood clot in the lungs (pulmonary embolism) confirmed by a CT scan in the last 72 hours - Your symptoms started within the last 7 days - If you are a woman who could become pregnant, you have had a negative pregnancy test - You agree to use contraception for the first 30 days of the study You may NOT be eligible if: - You have had a previous blood clot in the lungs - You have been on blood thinning medication for more than 72 hours - You have received clot-dissolving (thrombolytic) therapy - You have kidney or liver problems - You have lung or chest cancer - You are currently pregnant or breastfeeding - You have had previous exposure to mouse- or human-derived antibodies as a treatment - Your life expectancy is less than 90 days Talk to your doctor about whether this trial might be right for you.